MONTRÉAL, July 26, 2016 /CNW Telbec/ - Following the completion of the combination with Baxalta last June, Shire is reviewing its site footprint company-wide. Today the company announced its intention to relocate its current Saint-Laurent and Mississauga offices to a single location in Toronto by the fall of 2017, subject to a suitable site being secured. As the most populous city in Canada with the largest biotech cluster in the country, Toronto provides proximity to multiple Shire stakeholders, including peer biotechnology companies and the life science communities that support them.
Shire is fully committed to supporting employees through the transition and providing adequate support based on individual circumstances.
There are currently 65 employees working at the Shire facilities in Saint-Laurent and 25 employees in Mississauga.
Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We have best-in-class products available in more than 100 countries across core therapeutic areas including Hematology, Immunology, Neuroscience, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; a growing franchise in Oncology; and an emerging, innovative pipeline in Ophthalmics.
SOURCE Shire Pharma Canada ULC
Image with caption: "Logo: Shire Pharma Canada ULC (CNW Group/Shire Pharma Canada ULC)". Image available at: http://photos.newswire.ca/images/download/20160726_C8613_PHOTO_EN_742247.jpg
For further information: Brigitte Viel, email@example.com, 514-243-1464